Search Results

SMi Trial™, ScienceMedia’s protocol compliance and risk-based training for clinical trials, is receiving outstanding praise from sponsors for their recently added training materials on recruiting diverse and underrepresented patient populations.

NanoString Technologies, Inc. announced the release of the first public dataset of the whole transcriptome obtained at true single-cell resolution on the CosMx™ Spatial Molecular Imager.

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, announced that the Company’s management will present at the SMi 13th Annual RNA Therapeutics Conference taking place virtually February 9-10, 2022.

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, Co-founder and CEO of Strand Therapeutics. They discuss how post-COVID, emerging platforms like circular and logic circuit RNA are expanding the field’s therapeutic horizons.

In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW’s Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and neuroscience are attracting fresh capital; and how “alpha stacking” shapes their investment edge in an age of chronic uncertainty. They cover topics discussed in RTW’s new book, “Innovation is the Best Medicine.”

ScienceMedia announces that SMi Trial’s fully mobile, fully compatible, just-in-time solution closes the loop in clinical trials. Clinical trials are embedded in a clinical process of humans caring for humans.

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing director, head of Biotech Private Equity at Ally Bridge Group, about how M &A dynamics, dealmaking and global partnerships are reshaping portfolio valuations and paths to growth in 2026.

ScienceMedia, the leader in life sciences and clinical trial education, has again demonstrated its commitment to innovation by launching a new version of SMi Trial , the company’s risk-based protocol training solution, and expanding the ScienceMedia team with the addition of a new Product Director, Robert Geckeler

In this episode of Denatured, Jennifer Smith-Parker speaks to Kenneth Galbraith, ⁠CEO of Zymeworks and Josh Smiley, president and COO of Zai Lab, about how renewed confidence is driving biotech entering 2026.

Biotech’s slump may finally be over in 2026. In interviews with BioSpace, Zymeworks’ CEO Ken Galbraith and Zai Lab’s President and COO Josh Smiley explain what’s fueling the comeback.